The long-standing edge that Novo Nordisk has held within the weight problems drug marketplace used to be thrown into query Friday when the corporate reported result of a intently watched candidate that fell wanting expectancies.
Novo reported that, in a late-stage learn about, a next-generation weight problems drug known as CagriSema led sufferers to lose 20% in their weight at 68 weeks when taking a look in any respect members — not up to the corporate’s personal projection of about 25% weight reduction. Novo’s inventory had tanked through just about 18% noon Friday.
Buyers had prime hopes for CagriSema — a mix of semaglutide, the energetic component in widespread therapies Ozempic and Wegovy, and cagrilintide, a remedy that turns on amylin and calcitonin receptors. The readout will most probably exacerbate issues about Novo’s talent to apply up at the good fortune of blockbusters Ozempic and Wegovy.
STAT+ Unique Tale
Have already got an account? Log in
This newsletter is unique to STAT+ subscribers
Free up this text — plus day-to-day protection and research of the pharma business — through subscribing to STAT+.
Have already got an account? Log in
Particular person plans
Crew plans
View All Plans
To learn the remainder of this tale subscribe to STAT+.
Subscribe
